Drug and vitamin studies leave bowel disease fatigue treatment uncertain
An integrative review reported possible benefits for several treatments, but limited evidence and mixed findings prevent firm conclusions about fatigue relief.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Some included studies reported less fatigue with thiamine, vedolizumab, upadacitinib or modafinil, but the review judged the available evidence insufficient. Thiamine results varied across studies, and vitamin B12 had not demonstrated a benefit. The abstract does not establish a preferred treatment or show that higher thiamine doses work better in a direct comparison.
The abstract provides no treatment effect sizes, confidence intervals, follow-up durations or comparator details. It also includes participants with irritable bowel syndrome, so the combined population is not exclusively people with inflammatory bowel disease.
Fatigue was the focus
Eligible studies had to assess fatigue as a primary objective and examine drug treatments in inflammatory bowel disease. The review therefore addresses fatigue relief; it does not establish effects on bowel inflammation, disease remission or work attendance.
Mixed reports need context
The review describes positive findings for some treatments alongside studies that did not show a benefit. Without details of comparison groups and study designs, these summaries cannot determine which option is more effective or how reliable each result is.
The original publication
PHARMACOLOGICAL TREATMENTS FOR FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTEGRATIVE REVIEW.
Morais T, Couto G, Rocha R et al.
Arq Gastroenterol · 2026
- PubMed ID
- 41538673
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.